,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Mr. Armando  Anido MBA', 'age': 64, 'title': 'Chairman & CEO', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 934535, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
1,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Ms. Terri B. Sebree', 'age': 64, 'title': 'Pres', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 729150, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
2,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Mr. James E. Fickenscher', 'age': 58, 'title': 'CFO & VP of Corp. Devel. (Leave of Absence)', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 607622, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
3,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Mr. Kenneth T. Jones', 'age': 58, 'title': 'VP, Corp. Controller & Interim CFO', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
4,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Mr. Albert P. Parker II', 'age': 56, 'title': 'Chief Legal Officer & Corp. Sec.', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
5,80 West Lancaster Avenue,Suite 300,Devon,PA,19333,United States,484 581 7505,https://www.zynerba.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.",25,"{'maxAge': 1, 'name': 'Mr. Joseph  Apostolico', 'title': 'VP of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.33,1.33,1.4,1.35,1.33,1.33,1.4,0.0,1.323651,-2.2063491,1451460,1451460,839250,672080,672080,1.38,1.39,4000,4000,74975768,0.25,1.4,0.81704,0.54997,0.0,0.0,USD,34388372,0.0,34854554,53939400,240624,40734,1690761600,1693440000,0.0045,0.060700003,0.12127,0.15,0.0047999998,0.575,2.4173913,1672444800,1703980800,1688083200,-37582088,-0.83,-0.63,-0.892,NCM,EQUITY,ZYNE,ZYNE,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",1438781400,America/New_York,EDT,-14400000,1.39,1.4,1.11,1.25,1.25,3.0,hold,2,35967516,0.713,-38564352,217879,3.254,3.43,0.751,-0.45106998,-0.87134004,-18789672,-31641956,0.0,0.0,0.0,USD,
